Exact Mass: 446.1698
Exact Mass Matches: 446.1698
Found 500 metabolites which its exact mass value is equals to given mass value 446.1698
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Thioproperazine
Thioproperazine is a potent neuroleptic with antipsychotic properties. Thioproperazine has a marked cataleptic and antiapomorphine activity associated with relatively slight sedative, hypothermic and spasmolytic effects. It is virtually without antiserotonin and hypotensive action and has no antihistaminic property. It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes. Overdosage may result in severe extrapyramidal symptoms with dysphagia, marked sialorrhea, persistent and rapidly increasing hyperthermia, pulmonary syndrome, state of shock with pallor and profuse sweating, which may be followed by collapse and coma. LD50 in mice is 70 mg/kg I.V., 120 mg/kg I.P., 500 mg/kg S.C. and 830 mg/kg P.O. N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Thioproperazine (RP 7843) is an orally active antipsychotic agent with calming, antiemetic activity. Thioproperazine is effective in promoting the release of dopamine in rat striatum. Thioproperazine can be used in studies of schizophrenia and bipolar disorder[1].
Osmanthuside A
Osmanthuside C is found in herbs and spices. Osmanthuside C is isolated from Osmanthus fragrans (sweet osmanthus). Isolated from Osmanthus fragrans (sweet osmanthus). Osmanthuside C is found in herbs and spices.
Gefitinib
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. [Wikipedia] L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
Crosatoside B
Crosatoside B is isolated from the pollen of Crocus sativus (saffron). Isolated from the pollen of Crocus sativus (saffron)
(S)-4-ethyl-4-hexanoyloxy-1,12-dihydro-4H-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14-dione|20-Hexanoyl-camptothecin|4(S)-ethyl-4-hexanoyl-1H-pyrano-[3,4:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione|O-hexanoyl-camptothecin
2H-1-Benzopyran-3,4-diol, 2-(3,4-dimethoxyphenyl)-3,4-dihydro-7,8-dimethoxy-, diacetate, [2R-(2.alpha.,3.alpha.,4.alpha.)]-
(2S,4R)-7,4-dihydroxy-6,8-dimethyl-4,2-oxidoflavan-5-O-beta-D-glucopyranoside|abacopterin F
phenethyl alcohol 8-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside|phenethyl alcohol 8-O-beta-D-glucopyranosyl-(1->2)-O-beta-D-glucopyranoside|phenethyl alcohol beta-D-(2-O-beta-D-glucopyranosyl)glucopyranoside|phenethyl beta-D-sophoroside|phenethyl O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside|Phenethylalcohol 8-O-??-D-glucopyranosyl-(1鈥樏傗垎2)-??-D-glucopyranoside|phenylethyl-O-beta-D-glucopyranosyl-(1->2)-beta-D-glucopyranoside
4-methoxybenzyl-O-alpha-L-rhamnopyranosyl (1->6)-beta-D-glucopyranoside
4-methoxy-2,5-dimethylphenyl alpha-L-arabinofuranosyl-(1->6)-beta-D-glucopyranoside|illoliganoside A
nepodin-8-O-beta-D-(60-O-trans-crotonoyl)glucopyranoside|rumexneposide A
7-O-beta-glucopyranosyl demethoxymatteucinol|demethoxymatteucinol-7-O-beta-D-glucopyranoside|demethoxymatteuocinol 7-O-glucopyranoside
5,6,6-Trimethoxy-4,10-dihydroxy-11,12-dimethyl-4,5-(epoxymethanoxy)-2,2-butanobiphenyl-3-carboxylic acid
7-beta-D-glucopyranosyloxymethyl-9-methoxy-5H-dibenzo[a,c][7]annulene-3,10-diol|subavenoside C
(1S)-1-(2-hydroxy-6-methylphenyl)ethanol 2-O-(6-O-alpha-L-arabinofuranosyl)-beta-D-glucopyranoside|juniperoside VII
4-hydroxyphenylethyl 4-O-beta-D-glucopyranosyl-(1->3)-O-alpha-L-rhamnopyranoside|strigoside
beta-hydroxy-phenylethyl-O-alpha-L-rhamnopyranosyl (1->6)-beta-D-glucopyranoside
2-phenylethyl 6-O-(beta-D-glucopyranosyl)-beta-D-glucopyranoside|2-phenylethyl 6-O-beta-D-glucopyranosyl-beta-D-glucopyranoside|2-phenylethyl beta-gentiobioside|phenethyl alcohol beta-D-glucopyranosyl(1- >6)-beta-D-O-glucopyranoside|phenethyl alcohol beta-D-glucopyranosyl-(1->6)-beta-D-glucopyranoside|phenethyl alcohol beta-gentiobioside
(-)-15-methoxypodorhizol|(-)-5-methoxypodorhizol|5-Methoxypodorhizol
(1R,2R)-1-(3-methoxy-4,5-methylenedioxyphenyl)-2-methyl-3-oxobutyl 3,4,5-trimethoxybenzoate|tsangin B
O-beta-D-Galactopyranosyl-(1->4)-O-beta-D-galactopyranosyl-(1->2)-L-erythritol
(1S,2R)-2-methyl-3-oxo-1-(3,4,5-trimethoxyphenyl)butyl 3-methoxy-4,5-methylenedioxybenzoate|tsangin A
C20H30O11_2-(4-Methoxyphenyl)ethyl 6-O-alpha-L-arabinopyranosyl-beta-D-glucopyranoside
C20H30O11_2-Phenylethyl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
(2R,3R,4S,5S,6R)-2-[2-(4-methoxyphenyl)ethoxy]-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-3,4,5-triol
Thioproperazine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AB - Phenothiazines with piperazine structure C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Thioproperazine (RP 7843) is an orally active antipsychotic agent with calming, antiemetic activity. Thioproperazine is effective in promoting the release of dopamine in rat striatum. Thioproperazine can be used in studies of schizophrenia and bipolar disorder[1].
(2R,3R,4S,5S,6R)-2-[2-(4-methoxyphenyl)ethoxy]-6-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxane-3,4,5-triol_major
Ala Asp Asn Gln
Ala Asp Gln Asn
Ala Glu Met Pro
Ala Glu Asn Asn
Ala Glu Pro Met
Ala Gly His Tyr
Ala Gly Asn Trp
Ala Gly Trp Asn
Ala Gly Tyr His
Ala His Gly Tyr
Ala His Tyr Gly
Ala Met Glu Pro
Ala Met Pro Glu
Ala Asn Asp Gln
Ala Asn Glu Asn
Ala Asn Gly Trp
Ala Asn Asn Glu
Ala Asn Gln Asp
Ala Asn Trp Gly
Ala Pro Glu Met
Ala Pro Met Glu
Ala Gln Asp Asn
Ala Gln Asn Asp
Ala Trp Gly Asn
Ala Trp Asn Gly
Ala Tyr Gly His
Cys Asp Ile Pro
Cys Asp Leu Pro
Cys Asp Pro Ile
Cys Asp Pro Leu
Cys Glu Pro Val
Cys Glu Val Pro
Cys His Ser Thr
Cys His Thr Ser
Cys Ile Asp Pro
Cys Ile Pro Asp
Cys Leu Asp Pro
Cys Leu Pro Asp
Cys Met Pro Pro
Cys Asn Asn Pro
Cys Asn Pro Asn
Cys Pro Asp Ile
Cys Pro Asp Leu
Cys Pro Glu Val
Cys Pro Ile Asp
Cys Pro Leu Asp
Cys Pro Met Pro
Cys Pro Asn Asn
Cys Pro Pro Met
Cys Pro Val Glu
Cys Ser His Thr
Cys Ser Thr His
Cys Thr His Ser
Cys Thr Ser His
Cys Val Glu Pro
Cys Val Pro Glu
Asp Ala Asn Gln
Asp Ala Gln Asn
Asp Cys Ile Pro
Asp Cys Leu Pro
Asp Cys Pro Ile
Asp Cys Pro Leu
Asp Asp Pro Thr
Asp Asp Thr Pro
Asp Glu Pro Ser
Asp Glu Ser Pro
Asp Gly Gln Gln
Asp Ile Cys Pro
Asp Ile Pro Cys
Asp Leu Cys Pro
Asp Leu Pro Cys
Asp Asn Ala Gln
Asp Asn Gln Ala
Asp Pro Cys Ile
Asp Pro Cys Leu
Asp Pro Asp Thr
Asp Pro Glu Ser
Asp Pro Ile Cys
Asp Pro Leu Cys
Asp Pro Ser Glu
Asp Pro Thr Asp
Asp Gln Ala Asn
Asp Gln Gly Gln
Asp Gln Asn Ala
Asp Gln Gln Gly
Asp Ser Glu Pro
Asp Ser Pro Glu
Asp Thr Asp Pro
Asp Thr Pro Asp
Glu Ala Met Pro
Glu Ala Asn Asn
Glu Ala Pro Met
Glu Cys Pro Val
Glu Cys Val Pro
Glu Asp Pro Ser
Glu Asp Ser Pro
Glu Gly Asn Gln
Glu Gly Gln Asn
Glu Met Ala Pro
Glu Met Pro Ala
Glu Asn Ala Asn
Glu Asn Gly Gln
Glu Asn Asn Ala
Glu Asn Gln Gly
Glu Pro Ala Met
Glu Pro Cys Val
Glu Pro Asp Ser
Glu Pro Met Ala
Glu Pro Ser Asp
Glu Pro Val Cys
Glu Gln Gly Asn
Glu Gln Asn Gly
Glu Ser Asp Pro
Glu Ser Pro Asp
Glu Val Cys Pro
Glu Val Pro Cys
Gly Asp Gln Gln
Gly Glu Asn Gln
Gly Glu Gln Asn
Gly Asn Glu Gln
Gly Asn Gln Glu
Gly Gln Asp Gln
Gly Gln Glu Asn
Gly Gln Asn Glu
Gly Gln Gln Asp
His Cys Ser Thr
His Cys Thr Ser
His Ser Cys Thr
His Ser Thr Cys
His Thr Cys Ser
His Thr Ser Cys
Ile Cys Asp Pro
Ile Cys Pro Asp
Ile Asp Cys Pro
Ile Asp Pro Cys
Ile Pro Cys Asp
Ile Pro Asp Cys
Leu Cys Asp Pro
Leu Cys Pro Asp
Leu Asp Cys Pro
Leu Asp Pro Cys
Leu Pro Cys Asp
Leu Pro Asp Cys
Met Ala Glu Pro
Met Ala Pro Glu
Met Cys Pro Pro
Met Glu Ala Pro
Met Glu Pro Ala
Met Pro Ala Glu
Met Pro Cys Pro
Met Pro Glu Ala
Met Pro Pro Cys
Asn Ala Asp Gln
Asn Ala Glu Asn
Asn Ala Asn Glu
Asn Ala Gln Asp
Asn Cys Asn Pro
Asn Cys Pro Asn
Asn Asp Ala Gln
Asn Asp Gln Ala
Asn Glu Ala Asn
Asn Glu Gly Gln
Asn Glu Asn Ala
Asn Glu Gln Gly
Asn Gly Glu Gln
Asn Gly Gln Glu
Asn Asn Ala Glu
Asn Asn Cys Pro
Asn Asn Glu Ala
Asn Asn Pro Cys
Asn Pro Cys Asn
Asn Pro Asn Cys
Asn Gln Ala Asp
Asn Gln Asp Ala
Asn Gln Glu Gly
Asn Gln Gly Glu
Pro Ala Glu Met
Pro Ala Met Glu
Pro Cys Asp Ile
Pro Cys Asp Leu
Pro Cys Glu Val
Pro Cys Ile Asp
Pro Cys Leu Asp
Pro Cys Met Pro
Pro Cys Asn Asn
Pro Cys Pro Met
Pro Cys Val Glu
Pro Asp Cys Ile
Pro Asp Cys Leu
Pro Asp Asp Thr
Pro Asp Glu Ser
Pro Asp Ile Cys
Pro Asp Leu Cys
Pro Asp Ser Glu
Pro Asp Thr Asp
Pro Glu Ala Met
Pro Glu Cys Val
Pro Glu Asp Ser
Pro Glu Met Ala
Pro Glu Ser Asp
Pro Glu Val Cys
Pro Ile Cys Asp
Pro Ile Asp Cys
Pro Leu Cys Asp
Pro Leu Asp Cys
Pro Met Ala Glu
Pro Met Cys Pro
Pro Met Glu Ala
Pro Met Pro Cys
Pro Asn Cys Asn
Pro Asn Asn Cys
Pro Pro Cys Met
Pro Pro Met Cys
Pro Ser Asp Glu
Pro Ser Glu Asp
Pro Thr Asp Asp
Pro Val Cys Glu
Pro Val Glu Cys
Gln Ala Asp Asn
Gln Ala Asn Asp
Gln Asp Ala Asn
Gln Asp Gly Gln
Gln Asp Asn Ala
Gln Asp Gln Gly
Gln Glu Gly Asn
Gln Glu Asn Gly
Gln Gly Asp Gln
Gln Gly Glu Asn
Gln Gly Asn Glu
Gln Gly Gln Asp
Gln Asn Ala Asp
Gln Asn Asp Ala
Gln Asn Glu Gly
Gln Asn Gly Glu
Gln Gln Asp Gly
Gln Gln Gly Asp
Ser Cys His Thr
Ser Cys Thr His
Ser Asp Glu Pro
Ser Asp Pro Glu
Ser Glu Asp Pro
Ser Glu Pro Asp
Ser His Cys Thr
Ser His Thr Cys
Ser Pro Asp Glu
Ser Pro Glu Asp
Ser Thr Cys His
Ser Thr His Cys
Thr Cys His Ser
Thr Cys Ser His
Thr Asp Asp Pro
Thr Asp Pro Asp
Thr His Cys Ser
Thr His Ser Cys
Thr Pro Asp Asp
Thr Ser Cys His
Thr Ser His Cys
Val Cys Glu Pro
Val Cys Pro Glu
Val Glu Cys Pro
Val Glu Pro Cys
Val Pro Cys Glu
Val Pro Glu Cys
Gefitinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents
Osmanthuside A
Crosatoside B
A glycosylglucose derivative that is alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranose in which the anomeric hydroxy hydrogen has been replaced by a 2-(4-hydroxyphenyl)ethyl group.
Ethyl 18-bromo-8E,17E19Z-tricosatrien-4,6-diynoate
2-(4-Methoxyphenyl)ethyl 6-O-?-L-arabinopyranosyl-?-D-glucopyranoside
Ethyl 18-bromo-8E,17E,19Z-tricosatrien-4,6-diynoate
3-[[4-[benzylethylamino]phenyl]azo]-1,2-dimethyl-1H-1,2,4-triazolium methyl sulphate
2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1,1-dimethyl-2-(1-methylethoxy)-2-oxoethyl ester
ethyl 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,8-naphthyridine-3-carboxylate
ethyl 1-(2,4-difluorophenyl)-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,8-naphthyridine-3-carboxylate
3-ETHYL-5-[(E,2E)-1-PHENYL-4-(1,3,3-TRIMETHYL-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)-2-BUTENYLIDENE]-2-THIOXO-1,3-THIAZOLIDIN-4-ONE
Cvt-6883
GS-6201 (CVT-6883) is a selective adenosine A2B receptor antagonist. GS-6201 displays high affinity and selectivity for the human adenosine A2B receptors (Ki=22 nM)[1]. GS-6201 reduces caspase-1 activity in the heart, and attenuates cardiac remodeling after acute myocardial infarction (AMI) in the mouse[2]. GS-62013 attenuates the airway reactivity induced by NECA, AMP, or allergen in sensitized mice[3].
(3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide
3-Deschloro-4-Desfluoro-4-Chloro-3-Fluoro Gefitinib
POLYPHENYL ETHER (5 RINGS) OS-124, STAT. PHASE FOR GC
(2E)-(R)-5-(diphenylamino)-5-oxopent-3-en-2-y13-(5-nitrocyclohex-1-en-1-y1)acylate
(1s,2r)-2-{[(1s)-1-[(1,3-Dioxo-1,3-Dihydro-2h-Isoindol-2-Yl)methyl]-3,4-Dihydroisoquinolin-2(1h)-Yl]carbonyl}cyclohexanecarboxylic Acid
N-(Deoxyguanosin-8-yl)-2-aminofluorene
D009676 - Noxae > D002273 - Carcinogens
3-benzyl-4-methyl-7-[(3,4,5-trimethoxybenzyl)oxy]-2H-chromen-2-one
(2S,4R)-1-Acetyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-(2-benzothiazolylcarbonyl)butyl]-4-hydroxy-2-pyrrolidinecarboxamide
2-[2-(4-Methoxyphenyl)ethoxy]-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxane-3,4,5-triol
(2S)-2-[[4-[[(6S)-2,4-dioxo-5,6,7,8-tetrahydro-1H-pteridin-6-yl]methylamino]benzoyl]amino]pentanedioic acid
2-(4-methoxyphenyl)ethyl 6-O-a-L-arabinopyranosyl-b-D-glucopyranoside
(1R,2S)-2-[[(1S)-1-[(1,3-dioxo-2-isoindolyl)methyl]-3,4-dihydro-1H-isoquinolin-2-yl]-oxomethyl]-1-cyclohexanecarboxylic acid
1-(4-amino-1,2,5-oxadiazol-3-yl)-N-[(E)-(3-phenylmethoxyphenyl)methylideneamino]-5-propan-2-yltriazole-4-carboxamide
4-[2-Nitro-5-[4-(phenylmethyl)sulfonyl-1-piperazinyl]phenyl]morpholine
N-[2-(cyclohexylthio)ethyl]-4-methyl-3-[(4-methylphenyl)sulfamoyl]benzamide
1-[3-[(E)-2-cyano-3-(furan-2-ylmethylamino)-3-oxoprop-1-enyl]-4-oxopyrido[1,2-a]pyrimidin-2-yl]piperidine-4-carboxamide
(1S,5R)-3-{[(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl)oxy]acetyl}-1,2,3,4,5,6-hexahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one
2-[[2-(5-chloro-2-methoxyanilino)-2-oxoethyl]-methylamino]-N-[2-(4-morpholinyl)phenyl]acetamide
N-[2-[(2S,5R,6S)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5S,6R)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6S)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6R)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5R,6R)-5-[(4-chlorophenyl)carbamoylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-2-pyridin-2-ylacetamide
[(1S,2aR,8bR)-1-(hydroxymethyl)-4-[(3-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-fluorophenyl)methanone
[(1R,2aR,8bR)-1-(hydroxymethyl)-4-[(3-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-fluorophenyl)methanone
N-[2-[(2R,5R,6R)-5-[(4-chlorophenyl)carbamoylamino]-6-(hydroxymethyl)oxan-2-yl]ethyl]-2-pyridin-2-ylacetamide
(2R)-2-[(4S,5S)-8-[2-(2-fluorophenyl)ethynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4R,5R)-8-[2-(2-fluorophenyl)ethynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[2-[(2R,5R,6S)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
2-[(1S,3S,4aS,9aR)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aS,9aR)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3S,4aR,9aS)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
(1S,2aS,8bS)-N-(3-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(2-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-N-(2-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(3-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aS,8bS)-N-(2-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(3-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
[(1R,2aS,8bS)-1-(hydroxymethyl)-4-[(3-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-fluorophenyl)methanone
[(1S,2aS,8bS)-1-(hydroxymethyl)-4-[(3-methoxyphenyl)-oxomethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinolin-2-yl]-(4-fluorophenyl)methanone
(6R,7S,8R)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(2R)-2-[(4R,5R)-8-[2-(2-fluorophenyl)ethynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
(2S)-2-[(4S,5S)-8-[2-(2-fluorophenyl)ethynyl]-4-methyl-5-(methylaminomethyl)-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
N-[2-[(2R,5S,6S)-5-[[(4-chloroanilino)-oxomethyl]amino]-6-(hydroxymethyl)-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
2-[(1R,3R,4aR,9aS)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3S,4aR,9aS)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3R,4aS,9aR)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1R,3S,4aS,9aR)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
2-[(1S,3R,4aR,9aS)-6-(benzenesulfonamido)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N,N-dimethylacetamide
(1S,2aR,8bR)-N-(3-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(2-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aR,8bR)-N-(3-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(2-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aS,8bS)-N-(3-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(2-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1R,2aS,8bS)-N-(2-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(3-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(1S,2aR,8bR)-N-(2-fluorophenyl)-1-(hydroxymethyl)-2-[1-oxo-2-(3-pyridinyl)ethyl]-1,2a,3,8b-tetrahydroazeto[2,3-c]quinoline-4-carboxamide
(6R,7S,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8R)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8R)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-4-[1,3-benzodioxol-5-yl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methylbut-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(2-fluorophenyl)-8-(hydroxymethyl)-2-oxo-7-[4-(3-pyridinyl)phenyl]-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
7,8-dimethoxy-2-phenyl-5-[(2S,4S,5R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] heptanoate
1-[2-({5-amino-1-[(1-carboxylato-2-hydroxyethyl)-c-hydroxycarbonimidoyl]pentyl}-c-hydroxycarbonimidoyl)-3,4-dihydroxyphenyl]-1λ⁵-pyridin-1-ylium
(2r,3r,4s)-2,3,10,10-tetramethyl-6-oxo-8-phenyl-3,4-dihydro-2h-1,5,9-trioxatriphenylen-4-yl acetate
(2s,3r,4s,5s,6r)-2-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-phenoxyoxan-3-yl]oxy}-2-ethyl-6-(hydroxymethyl)oxane-3,4,5-triol
2-methyl-3-oxo-1-(3,4,5-trimethoxyphenyl)butyl 7-methoxy-2h-1,3-benzodioxole-5-carboxylate
2-[(4-methoxyphenyl)methoxy]-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxane-3,4,5-triol
(2s,3s,4r,5r,6s)-2-[(4-methoxyphenyl)methoxy]-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxane-3,4,5-triol
3-chloro-2-(3,7-dimethylocta-2,6-dien-1-yl)-2,5,7-trihydroxy-3-(3-methylbut-2-en-1-yl)naphthalene-1,4-dione
5-butoxy-7-(hydroxymethyl)-1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,4ah,5h,7ah-cyclopenta[c]pyran-4-carboxylic acid
ethyl (8e,17e,19e)-18-bromotricosa-8,17,19-trien-4,6-diynoate
3-(hydroxymethyl)-4-[(7-methoxy-2h-1,3-benzodioxol-5-yl)(3,4,5-trimethoxyphenyl)methyl]oxolan-2-one
[(2r,3s,4s,5r,6s)-6-[(7-acetyl-8-hydroxy-6-methylnaphthalen-1-yl)oxy]-3,4,5-trihydroxyoxan-2-yl]methyl (2e)-but-2-enoate
(2r,3r,4s,5s,6r)-2-{[(2r,3r,4s,5s,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-(2-phenylethoxy)oxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
[(2r,3s,4s,5r)-3,4,5-trihydroxy-6-(4-hydroxy-2,3-dimethylphenoxy)oxan-2-yl]methyl (2e)-3-(4-hydroxyphenyl)prop-2-enoate
(9r,10r,11r)-5,11-dihydroxy-3,4,19-trimethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.0²,⁷.0¹⁴,¹⁸]nonadeca-1(12),2,4,6,13,18-hexaene-6-carboxylic acid
2-methyl-6-{[3,4,5-trihydroxy-6-(2-hydroxy-2-phenylethoxy)oxan-2-yl]methoxy}oxane-3,4,5-triol
1-(1-hydroxyethyl)-4β-rutinosyloxybenzene
{"Ingredient_id": "HBIN000442","Ingredient_name": "1-(1-hydroxyethyl)-4\u03b2-rutinosyloxybenzene","Alias": "NA","Ingredient_formula": "C20H30O11","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10105","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
4-hydroxyphenylethyl 4-o-β-d-glucopyranosyl-(1→3)-o-α-l-rhamnopyranoside
{"Ingredient_id": "HBIN010566","Ingredient_name": "4-hydroxyphenylethyl 4-o-\u03b2-d-glucopyranosyl-(1\u21923)-o-\u03b1-l-rhamnopyranoside","Alias": "NA","Ingredient_formula": "C20H30O11","Ingredient_Smile": "CC1C(C(C(C(O1)OC2=CC=C(C=C2)CCO)O)OC3C(C(C(C(O3)CO)O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10619","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}